Pre-clinical studies for the effects of CBD and analogues for the treatment of osteoarthritis
The aim of this study is to evaluate topical applications of cannabidiol (CBD), an active constituent of marijuana, or endocannabinoid analogues [linoleoylethanolamide (LEA), oleoyl ethanolamide (OEA), and palmitoylethanolamide (PEA)] applied as topical patches, to reduce joint pain in OA patients. This study will provide valuable information, into the much needed, pharmacokinetics of endocannabinoids and their effectiveness/utility in pain relief. By using CBD or endocannabinoid analogues that stimulate only the cannabinoid 2 receptor (CB2) it is hypothesised that the previously published side effects of drowsiness and confusion (CB1 effects) will not be observed and the patients will benefit from pain relief.
This study is novel in the use of compounds not previously tested (OEA, LEA, PEA) in OA; the effectiveness of transdermal administration of these drugs in humans; and the development of a unique patch delivery system. The application of these finding will have a direct impact on individuals with pain providing analgesia and anti-inflammatory effects without the hallucinations or drowsiness often noted with marijuana; create a new delivery system; provide valuable information on CBD, OEA and PEA in patients with OA that can form a platform for future studies and adaptation into clinical practice.
The opportunity ID for this research opportunity is 22